An open label, interventional, multi-center, prospective clinical study to evaluate efficacy and safety of â??Ayuvigo Forte Capsuleâ?? in patients suffering from mild to moderate erectile dysfunction - NI

Welex Laboratories Pvt Ltd0 个研究点目标入组 38 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Subjects who have scored 13 to 24 on the Erectile Function (EF) domain of the International Index of Erectile Function (IIEF) at screening.
•2. Subject without any organic cause of Erectile Dysfunction.
•3. Subjects should be in an active stable sexual relationship for the duration of study
•4. Subject willing to participate in clinical trial and who have read, understood and signed informed consent form

•1. Subjects with total erectile failure or any other sexual disorder
•2. Subjects with history of disorders that may cause priapism
•3. Subjects with history of central nervous system disorders such as stroke, transient ischemic attacks or spinal cord injury or pelvic surgery
•4. Subjects with hypotension or uncontrolled hypertension, uncontrolled diabetes, hepatic impairment, renal impairment or hematological disorders
•5. Subjects who are using and or dependency or failure to keep abstinence for antioxidant agents, vitamins, anti-inflammatory drugs, hormones, Ayurvedic, herbal, homeopathic, naturopathy medications for erectile dysfunction
•6. Patients with preexisting systemic disease necessitating long-term medications, genetic and endocrinal disorders
•7. Continuing history of alcohol and or drug abuse
•8. ECG demonstrating any signs of uncontrolled arrhythmia, acute ischemia and X- ray chest showing any active lesion of tuberculosis
•9. Subjects with significant abnormal laboratory parameters

发起方

Welex Laboratories Pvt Ltd